Early treatment of multiple sclerosis: A Latin American Experts Meeting
Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognos...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2009-10, Vol.15 (3_suppl), p.1-12 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | 3_suppl |
| container_start_page | 1 |
| container_title | Multiple sclerosis |
| container_volume | 15 |
| creator | Garcea, O Villa1, A Cáceres, F Adoni, T Alegría, M Thomaz, R Barbosa Buzo, R Lopez, L Llamas Kindel, M Rivera |
| description | Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients. Multiple Sclerosis 2009; 15: S1–S12. http://msj.sagepub.com |
| doi_str_mv | 10.1177/1352458509106419 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733675429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458509106419</sage_id><sourcerecordid>733675429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c278t-355a8e9ac70392517c392f78aa2d706efeea6b21c0cc8c5aded1e8335638ec273</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlbvniR48bSabDZf3kqpVah40fOSZmfLlv0yyYL9901poVDwNCHzzDPJi9A9Jc-USvlCGU8zrjjRlIiM6gs0ppmUCdGSXMZzbCf7_gjdeL8hhEjJ-DUaUa0F51yM0WJuXL3FwYEJDbQBdyVuhjpUfQ3Y2xpc5yv_iqd4aULV4mkDrrKmxfO_Hlzw-BMg3q9v0VVpag93xzpBP2_z79l7svxafMymy8SmUoWEcW4UaGMlYTrlVNpYSqmMSQtJBJQARqxSaom1ynJTQEFBMcYFUxAVbIKeDt7edb8D-JA3lbdQ16aFbvC5ZExInqU6ko9n5KYbXBsfl6dURafI9jpygGz8p3dQ5r2rGuO2OSX5PuL8POI48nD0DqsGitPAMdMIJAfAmzWclv4r3AH6goIg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218833647</pqid></control><display><type>article</type><title>Early treatment of multiple sclerosis: A Latin American Experts Meeting</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Garcea, O ; Villa1, A ; Cáceres, F ; Adoni, T ; Alegría, M ; Thomaz, R Barbosa ; Buzo, R ; Lopez, L Llamas ; Kindel, M Rivera</creator><creatorcontrib>Garcea, O ; Villa1, A ; Cáceres, F ; Adoni, T ; Alegría, M ; Thomaz, R Barbosa ; Buzo, R ; Lopez, L Llamas ; Kindel, M Rivera</creatorcontrib><description>Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients. Multiple Sclerosis 2009; 15: S1–S12. http://msj.sagepub.com</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458509106419</identifier><identifier>PMID: 19965556</identifier><identifier>CODEN: MUSCFZ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Biomarkers ; Cognition Disorders - etiology ; Cognition Disorders - psychology ; Congresses as Topic ; Disease Progression ; Humans ; Immunoglobulin G - therapeutic use ; Immunologic Factors - therapeutic use ; Latin America ; Magnetic Resonance Imaging ; Meta-Analysis as Topic ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - therapy ; Prognosis ; Randomized Controlled Trials as Topic ; Risk Assessment ; Steroids - therapeutic use</subject><ispartof>Multiple sclerosis, 2009-10, Vol.15 (3_suppl), p.1-12</ispartof><rights>2009 SAGE Publications</rights><rights>SAGE Publications © Oct 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c278t-355a8e9ac70392517c392f78aa2d706efeea6b21c0cc8c5aded1e8335638ec273</citedby><cites>FETCH-LOGICAL-c278t-355a8e9ac70392517c392f78aa2d706efeea6b21c0cc8c5aded1e8335638ec273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458509106419$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458509106419$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21802,27907,27908,43604,43605</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19965556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcea, O</creatorcontrib><creatorcontrib>Villa1, A</creatorcontrib><creatorcontrib>Cáceres, F</creatorcontrib><creatorcontrib>Adoni, T</creatorcontrib><creatorcontrib>Alegría, M</creatorcontrib><creatorcontrib>Thomaz, R Barbosa</creatorcontrib><creatorcontrib>Buzo, R</creatorcontrib><creatorcontrib>Lopez, L Llamas</creatorcontrib><creatorcontrib>Kindel, M Rivera</creatorcontrib><title>Early treatment of multiple sclerosis: A Latin American Experts Meeting</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients. Multiple Sclerosis 2009; 15: S1–S12. http://msj.sagepub.com</description><subject>Biomarkers</subject><subject>Cognition Disorders - etiology</subject><subject>Cognition Disorders - psychology</subject><subject>Congresses as Topic</subject><subject>Disease Progression</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Latin America</subject><subject>Magnetic Resonance Imaging</subject><subject>Meta-Analysis as Topic</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - therapy</subject><subject>Prognosis</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Steroids - therapeutic use</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlbvniR48bSabDZf3kqpVah40fOSZmfLlv0yyYL9901poVDwNCHzzDPJi9A9Jc-USvlCGU8zrjjRlIiM6gs0ppmUCdGSXMZzbCf7_gjdeL8hhEjJ-DUaUa0F51yM0WJuXL3FwYEJDbQBdyVuhjpUfQ3Y2xpc5yv_iqd4aULV4mkDrrKmxfO_Hlzw-BMg3q9v0VVpag93xzpBP2_z79l7svxafMymy8SmUoWEcW4UaGMlYTrlVNpYSqmMSQtJBJQARqxSaom1ynJTQEFBMcYFUxAVbIKeDt7edb8D-JA3lbdQ16aFbvC5ZExInqU6ko9n5KYbXBsfl6dURafI9jpygGz8p3dQ5r2rGuO2OSX5PuL8POI48nD0DqsGitPAMdMIJAfAmzWclv4r3AH6goIg</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Garcea, O</creator><creator>Villa1, A</creator><creator>Cáceres, F</creator><creator>Adoni, T</creator><creator>Alegría, M</creator><creator>Thomaz, R Barbosa</creator><creator>Buzo, R</creator><creator>Lopez, L Llamas</creator><creator>Kindel, M Rivera</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200910</creationdate><title>Early treatment of multiple sclerosis: A Latin American Experts Meeting</title><author>Garcea, O ; Villa1, A ; Cáceres, F ; Adoni, T ; Alegría, M ; Thomaz, R Barbosa ; Buzo, R ; Lopez, L Llamas ; Kindel, M Rivera</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c278t-355a8e9ac70392517c392f78aa2d706efeea6b21c0cc8c5aded1e8335638ec273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Biomarkers</topic><topic>Cognition Disorders - etiology</topic><topic>Cognition Disorders - psychology</topic><topic>Congresses as Topic</topic><topic>Disease Progression</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Latin America</topic><topic>Magnetic Resonance Imaging</topic><topic>Meta-Analysis as Topic</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - therapy</topic><topic>Prognosis</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Steroids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcea, O</creatorcontrib><creatorcontrib>Villa1, A</creatorcontrib><creatorcontrib>Cáceres, F</creatorcontrib><creatorcontrib>Adoni, T</creatorcontrib><creatorcontrib>Alegría, M</creatorcontrib><creatorcontrib>Thomaz, R Barbosa</creatorcontrib><creatorcontrib>Buzo, R</creatorcontrib><creatorcontrib>Lopez, L Llamas</creatorcontrib><creatorcontrib>Kindel, M Rivera</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcea, O</au><au>Villa1, A</au><au>Cáceres, F</au><au>Adoni, T</au><au>Alegría, M</au><au>Thomaz, R Barbosa</au><au>Buzo, R</au><au>Lopez, L Llamas</au><au>Kindel, M Rivera</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early treatment of multiple sclerosis: A Latin American Experts Meeting</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2009-10</date><risdate>2009</risdate><volume>15</volume><issue>3_suppl</issue><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><coden>MUSCFZ</coden><abstract>Patients with clinically isolated syndrome (CIS) by definition do not have multiple sclerosis (MS) but are at risk of developing it. While studies show earlier immunomodulating drug use is effective, treatment must consider likely patient prognosis. In this paper we review current diagnosis, prognosis, and treatment literature for patients with CIS within Latin American clinical settings. Latin American MS experts, convened by ACINDES (The Civil Association for Research and Development in Health), reviewed current CIS (and early MS) literature and drew consensus conclusions. Three subgroups addressed separate questionnaires on CIS issues: prognosis, diagnosis, and treatment. MRI can contribute to predicting MS risk in patients with CIS; in Latin America, investigation of haplotype presence associated with CIS would be appropriate. McDonald's criteria and subsequent revisions enable earlier, more accurate MS diagnosis. Type A evidence exists supporting all leading immunomodulating MS drugs for effective treatment of CIS with a high risk of conversion to MS. In conclusion, patients with CIS are usually young, with often-limited symptomatic manifestations, and must be adequately prepared to receive preventive treatment. This consensus review should contribute to the dialogue between physicians and patients. Multiple Sclerosis 2009; 15: S1–S12. http://msj.sagepub.com</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>19965556</pmid><doi>10.1177/1352458509106419</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2009-10, Vol.15 (3_suppl), p.1-12 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733675429 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Biomarkers Cognition Disorders - etiology Cognition Disorders - psychology Congresses as Topic Disease Progression Humans Immunoglobulin G - therapeutic use Immunologic Factors - therapeutic use Latin America Magnetic Resonance Imaging Meta-Analysis as Topic Multiple Sclerosis - diagnosis Multiple Sclerosis - therapy Prognosis Randomized Controlled Trials as Topic Risk Assessment Steroids - therapeutic use |
| title | Early treatment of multiple sclerosis: A Latin American Experts Meeting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A43%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20treatment%20of%20multiple%20sclerosis:%20A%20Latin%20American%20Experts%20Meeting&rft.jtitle=Multiple%20sclerosis&rft.au=Garcea,%20O&rft.date=2009-10&rft.volume=15&rft.issue=3_suppl&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=1352-4585&rft.eissn=1477-0970&rft.coden=MUSCFZ&rft_id=info:doi/10.1177/1352458509106419&rft_dat=%3Cproquest_cross%3E733675429%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218833647&rft_id=info:pmid/19965556&rft_sage_id=10.1177_1352458509106419&rfr_iscdi=true |